Reading press releases is one of the most important (and often overlooked) aspects of microcap research. Yet, reviewing them across multiple financial news wires is often cumbersome and time-consuming. To address this challenge, my team and I are in the early innings of developing a specialized tool called PRaaP (Press Releases as a Platform). It centralizes press releases from various sources, provides core data such as share counts, basic fundamentals, and charts, and allows for advanced filtering based on price, market cap, outstanding shares and news category.

Our open forum events often kick off with an introduction, where I talk about some things that are on my mind. February’s introduction was inspired by a conversation I had with a colleague.
Our decision to add a medical device stock to the Run to One Dollar Model Portfolio a couple weeks ago was met with some skepticism from a colleague who questioned our rationale, particularly regarding dilution and profitability metrics. We had just spoken with the management of the company and are fairly impressed with the direction that the company is heading, while acknowledging that there still may be some bumps along the way.

We are adding a niche medical device company to our Run to One (R21) Model Portfolio. It is an under-the-radar growth story where management believes the company’s specialized products, rapid manufacturing capabilities, and disciplined financial execution give it a competitive edge in a traditionally slow-moving industry.